Publikationen in Zusammenarbeit mit Forschern von Complejo Asistencial Universitario de León (29)

2024

  1. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  2. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Incidence, and natural history of inflammatory bowel disease in Castilla y León: Prospective and multicenter epidemiological study

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 102-108

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Coeliac disease in elderly patients: Value of coeliac lymphogram for diagnosis

    Nutrients, Vol. 13, Núm. 9

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Infliximab in ulcerative colitis: Real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study)

    Scandinavian Journal of Gastroenterology, Vol. 51, Núm. 2, pp. 186-195

2015

  1. Resources utilization and costs the year before and after starting treatment with adalimumab in Crohn's disease patients

    Inflammatory Bowel Diseases, Vol. 21, Núm. 7, pp. 1631-1640

2014

  1. Conflictos éticos en el establecimiento de niveles asistenciales en la trisomía 18

    Anales de Pediatria

  2. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2013

  1. Do serum C-reactive protein and Interleukin-6 predict kidney scarring after urinary tract infection?

    Indian Journal of Pediatrics, Vol. 80, Núm. 12, pp. 1002-1006

2009

  1. Anemia crónica como forma de presentación de linfangioma abdominal

    Anales de Pediatria

  2. Neutropenia cíclica: tratamiento con factor estimulante de colonias de granulocitos recombinante en un caso de novo

    Anales de Pediatria

2008

  1. Celiac disease

    Medicina Clinica, Vol. 131, Núm. 7, pp. 264-270

  2. Urinary interleukin-6 is useful in distinguishing between upper and lower urinary tract infections

    Pediatric Nephrology, Vol. 23, Núm. 3, pp. 429-433